Mer­ck dou­bles down on Mod­er­na's mR­NA can­cer vac­cines, pay­ing $125M to part­ner on KRAS shared anti­gen strat­e­gy

Mer­ck and its R&D chief Roger Perl­mut­ter are bet­ting big on their re­la­tion­ship with Mod­er­na, pay­ing $125 mil­lion for a chunk of Se­ries H eq­ui­ty in the mes­sen­ger RNA pi­o­neer as they add a ma­jor col­lab­o­ra­tion on an off-the-shelf ap­proach to can­cers with KRAS mu­ta­tions.

In an in­ter­view pre­view­ing the an­nounce­ment, CEO Stephane Ban­cel and can­cer re­search chief Tal Zaks not­ed that Mer­ck plans to test this in com­bi­na­tion with Keytru­da, its star check­point in­hibitor, which has faced a tough chal­lenge in KRAS.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.